MyFinsight
Home
Blog
About
Contact
Download
Download image
Thereafter
$65,232K
2030
$5,544K
2029
$5,544K
2028
$5,544K
2027
$5,544K
2026
$5,544K
Thereafter
$6,822K
2030
$1,463K
2029
$1,463K
2028
$1,463K
2027
$1,463K
2026
$1,463K
Thereafter
$5,295K
2030
$941K
2029
$941K
2028
$941K
2027
$941K
2026
$941K
Marketable securities
$178,996K
Cash and cash
equivalents
$84,851K
Accounts receivable, net
$54,578K
Prepaid expenses and
other current assets
$26,985K
Inventory
$1,852K
PONVORY
$92,952K
Hetlioz
$14,137K
Nereus
$10,000K
Total current assets
$347,262K
Intangible assets, net
$117,089K
Non-current inventory and
other
$11,083K
Finance lease
right-of-use assets
$7,343K
Operating lease
right-of-use assets
$3,923K
Property and equipment,
net
$2,248K
Total assets
$488,948K
Total liabilities and
stockholders equity
$488,948K
Total stockholders
equity
$327,186K
Total liabilities
$161,762K
Accumulated deficit
-$394,766K
Additional paid-in capital
$721,264K
Total current
liabilities
$145,162K
Other non-current
liabilities
$9,533K
Finance lease
non-current liabilities
$4,076K
Operating lease
non-current liabilities
$2,991K
Accumulated other
comprehensive income
$629K
Common stock, 0.001 par
value 150,000,000...
$59K
Product revenue
allowances
$76,865K
Accounts payable and
accrued liabilities
$68,297K
Back
Back
Balance Sheet
source: myfinsight.com
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)